Details of the Drug

General Information of Drug (ID: DMCD9YG)

• Drug Name: Prazosin
• Synonyms: Furazosin; Justac; Lentopres; Prazocin; Prazosina; Prazosine; Prazosinum; Prazosin HCl; TNP00312; CP-12299; Hypovase (TN); Minipress (TN); Prazosin (INN); Prazosin [INN:BAN]; Prazosina [INN-Spanish]; Prazosine [INN-French]; Prazosinum [INN-Latin]; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); 1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone

Indication

Disease Entry	ICD 11	Status	REF
Benign prostatic hyperplasia	GA90	Approved	[1]
Congestive heart failure	BD10	Approved	[1]
Hypertension	BA00-BA04	Approved	[1]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 383.4
  Topological Polar Surface Area (xlogp); 2
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 8
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
  Bioavailability: 68% of drug becomes completely available to its intended biological destination(s) [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 4.7 mL/min/kg [4]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.49 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.06% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.73 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 1.4 mg/mL [2]
• Chemical Identifiers:
  Formula: C19H21N5O4
  IUPAC Name: [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
  Canonical SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC
  InChI: InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
  InChIKey: IENZQIKPVFGBNW-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4893
  ChEBI ID: CHEBI:8364
  CAS Number: 19216-56-9
  DrugBank ID: DB00457
  TTD ID: D0WV3U
  VARIDT ID: DR00693
  INTEDE ID: DR1330
  ACDINA ID: D00550

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-1 (ADRA1)	TTG28O6	NOUNIPROTAC	Antagonist	[6], [7]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[8]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[9]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A1 (CYP1A1) Main DME	DE6OQ3W	CP1A1_HUMAN	Substrate	[11]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Prazosin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Prazosin and Carvedilol.	Heart failure [BD10-BD1Z]	[53]

Coadministration of a Drug Treating the Disease Different from Prazosin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Prazosin and Linezolid.	Bacterial infection [1A00-1C4Z]	[54]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Prazosin and Cariprazine.	Bipolar disorder [6A60]	[55]
Sotalol	DML60TN	Moderate	Additive hypotensive effects by the combination of Prazosin and Sotalol.	Cardiac arrhythmia [BC9Z]	[53]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Prazosin and Olopatadine.	Conjunctiva disorder [9A60]	[56]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Prazosin and Selegiline.	Depression [6A70-6A7Z]	[54]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Prazosin and Isocarboxazid.	Depression [6A70-6A7Z]	[54]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Prazosin and Tranylcypromine.	Depression [6A70-6A7Z]	[54]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Prazosin and OPC-34712.	Depression [6A70-6A7Z]	[55]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Prazosin and Phenelzine.	Depression [6A70-6A7Z]	[54]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Prazosin and Nadolol.	Essential hypertension [BA00]	[53]
Carteolol	DMFMDOB	Moderate	Additive hypotensive effects by the combination of Prazosin and Carteolol.	Glaucoma [9C61]	[53]
Metipranolol	DMJMVKI	Moderate	Additive hypotensive effects by the combination of Prazosin and Metipranolol.	Glaucoma [9C61]	[53]
Levobetaxolol	DMSREPX	Moderate	Additive hypotensive effects by the combination of Prazosin and Levobetaxolol.	Glaucoma [9C61]	[53]
Levobunolol	DMTNFCQ	Moderate	Additive hypotensive effects by the combination of Prazosin and Levobunolol.	Glaucoma [9C61]	[53]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Prazosin and Procarbazine.	Hodgkin lymphoma [2B30]	[54]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Prazosin and Acebutolol.	Hypertension [BA00-BA04]	[53]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Prazosin and Moexipril.	Hypertension [BA00-BA04]	[57]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Prazosin and Bisoprolol.	Hypertension [BA00-BA04]	[53]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Prazosin and Captopril.	Hypertension [BA00-BA04]	[57]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Prazosin and Penbutolol.	Hypertension [BA00-BA04]	[53]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Prazosin and Trandolapril.	Hypertension [BA00-BA04]	[57]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Prazosin and Nebivolol.	Hypertension [BA00-BA04]	[53]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Prazosin and Fosinopril.	Hypertension [BA00-BA04]	[57]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Prazosin and Pindolol.	Hypertension [BA00-BA04]	[53]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Prazosin and Benazepril.	Hypertension [BA00-BA04]	[57]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Prazosin and Labetalol.	Hypertension [BA00-BA04]	[53]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Prazosin and Enalapril.	Hypertension [BA00-BA04]	[57]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Prazosin and Perindopril.	Hypertension [BA00-BA04]	[57]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Prazosin and Quinapril.	Hypertension [BA00-BA04]	[57]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Prazosin and Lisinopril.	Hypertension [BA00-BA04]	[57]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Prazosin and Propiomazine.	Insomnia [7A00-7A0Z]	[55]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Prazosin and ITI-007.	Insomnia [7A00-7A0Z]	[55]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Prazosin and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[58]
Propranolol	DM79NTF	Moderate	Additive hypotensive effects by the combination of Prazosin and Propranolol.	Migraine [8A80]	[53]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Prazosin and Lasmiditan.	Migraine [8A80]	[59]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Prazosin and Thalidomide.	Multiple myeloma [2A83]	[60]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Prazosin and Ozanimod.	Multiple sclerosis [8A40]	[54]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Prazosin and Promethazine.	Nausea/vomiting [MD90]	[55]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Prazosin and Safinamide.	Parkinsonism [8A00]	[54]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Prazosin and Rasagiline.	Parkinsonism [8A00]	[54]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Prazosin and Tamsulosin.	Prostate hyperplasia [GA90]	[61]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Prazosin and Silodosin.	Prostate hyperplasia [GA90]	[61]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Prazosin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[55]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Prazosin and Fluphenazine.	Psychotic disorder [6A20-6A25]	[55]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Prazosin and Triflupromazine.	Psychotic disorder [6A20-6A25]	[55]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Prazosin and Quetiapine.	Schizophrenia [6A20]	[55]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Prazosin and Mesoridazine.	Schizophrenia [6A20]	[55]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Prazosin and Thioridazine.	Schizophrenia [6A20]	[55]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Prazosin and Aripiprazole.	Schizophrenia [6A20]	[55]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Prazosin and Paliperidone.	Schizophrenia [6A20]	[55]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Prazosin and Haloperidol.	Schizophrenia [6A20]	[55]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Prazosin and Perphenazine.	Schizophrenia [6A20]	[55]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Prazosin and Molindone.	Schizophrenia [6A20]	[55]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Prazosin and Chlorpromazine.	Schizophrenia [6A20]	[55]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Prazosin and Thiothixene.	Schizophrenia [6A20]	[55]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Prazosin and Trifluoperazine.	Schizophrenia [6A20]	[55]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Prazosin and Risperidone.	Schizophrenia [6A20]	[55]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Prazosin and Amisulpride.	Schizophrenia [6A20]	[55]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Prazosin and Asenapine.	Schizophrenia [6A20]	[55]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Prazosin and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[55]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Prazosin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[62]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Prazosin 2 mg capsule	2 mg	Oral Capsule	Oral
Prazosin 1 mg capsule	1 mg	Oral Capsule	Oral
Prazosin 5 mg capsule	5 mg	Oral Capsule	Oral
Prazosin Hydrochloride eq 5mg base capsule	eq 5mg base	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] BDDCS applied to over 900 drugs
• [3] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33.
• [7] Characterization of alpha-adrenoceptor subtypes in smooth muscle of equine ileum. Am J Vet Res. 2001 Sep;62(9):1370-4.
• [8] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [9] P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res. 2011 Jan 25;1370:238-45.
• [10] Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9.
• [11] Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.
• [12] Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
• [13] Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
• [14] Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
• [15] Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
• [16] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [17] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [18] A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
• [19] Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
• [20] Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
• [21] Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
• [22] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [23] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [24] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [25] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [26] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [27] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [28] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [29] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [30] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [31] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [32] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [33] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [34] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [35] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [36] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [37] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [38] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [39] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [40] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [41] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [42] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [43] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [44] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [45] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [46] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [47] Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6.
• [48] Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505.
• [49] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [50] Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35.
• [51] Metazosin tablets (Kenosin) in the treatment of chronic congestive heart failure. Cas Lek Cesk. 1995 Sep 20;134(18):590-3.
• [52] Antihypertensive and Hypolipidemic Effects of DC-015, a Novel, Potent and Specific alpha(1)-Adrenoceptor Antagonist: Comparison with Prazosin in Spontaneously Hypertensive Rats. J Biomed Sci. 1996 Apr;3(2):108-116.
• [53] Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
• [54] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [55] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [56] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [57] Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
• [58] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [59] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [60] Cerner Multum, Inc. "Australian Product Information.".
• [61] Product Information. Flomax (tamsulosin). Boehringer-Ingelheim, Ridgefield, CT.
• [62] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.